We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
Read MoreHide Full Article
Endo International plc is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell. The company has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.3%.
Last quarter, the company delivered a positive earnings surprise of 24.69%.
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past year. Specifically, the stock lost 73.5% during this period in comparison to industry’s gain of 2.2%.
Let's see how things are shaping up for this quarter.
Factors Influencing This Quarter
Concurrent with the third-quarter results, Endo reiterated its outlook for 2016. The company continues to expect revenues in the range of $3.87 billion to $4.03 billion. It expects earnings in the range of $4.50 to $4.80 per share.
Endo’s top line should continue to benefit from robust performance of Xiaflex, sterile injectables and alternative dosages. The branded segment performed better than expected in the third quarter. Xiaflex experienced strong demand particularly in Peyronie's disease and the drug is expected to grow in the low-double-digits in 2017. However, since the announcement of the CDC guidelines, Endo continues to witness pressure in terms of prescription volumes in the opioid space.
The company also expects to see a modest decline in pain products. In addition, the earlier-than-expected generic entrant of Voltaren Gel has affected the 2016 outlook. Moreover, the reimbursement restrictions for Lidoderm further limit the use of the drug. The company thus expects Lidoderm sales to decline modestly. Endo expects a mid-to-high teen decline at the segment in 2016.
The Generics base business continues to be under pressure with revenues declining approximately 20% sequentially in third-quarter 2016. The decline can be attributed to deepening consortium pricing pressures, additional competitive entrants, product discontinuations as well as discrete factors, including destocking and shifts in purchase timing due to market conditions.
The business is expected to decline in low 30s in 2016. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid-cycles, could weigh on the company’s Generics business in the future and are likely to impact the adjusted gross margin profile.
On the fourth-quarter call, investors are expected to focus on the company’s performance. Updates on its restructuring efforts across the Generics product and R&D portfolio, as well as its manufacturing facility network are also expected by the investors.
Earnings Whispers
Our proven model does not conclusively show that Endo is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at -1.84%. This is because the Most Accurate estimate stands at $1.60 while the Zacks Consensus Estimate stand is pegged at $1.63. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Endo currently carries a Zacks Rank #5 (Strong Sell). As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
The Earnings ESP for Exelixis, Inc. (EXEL - Free Report) is +200% and it carries a Zacks Rank #2. The company is slated to release results on Feb 27.
Tesaro, Inc. has an Earnings ESP of +2.55% and a Zacks Rank #3. The company is scheduled to release results on Feb 28.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
Endo International plc is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell. The company has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.3%.
Last quarter, the company delivered a positive earnings surprise of 24.69%.
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past year. Specifically, the stock lost 73.5% during this period in comparison to industry’s gain of 2.2%.
Let's see how things are shaping up for this quarter.
Factors Influencing This Quarter
Concurrent with the third-quarter results, Endo reiterated its outlook for 2016. The company continues to expect revenues in the range of $3.87 billion to $4.03 billion. It expects earnings in the range of $4.50 to $4.80 per share.
Endo’s top line should continue to benefit from robust performance of Xiaflex, sterile injectables and alternative dosages. The branded segment performed better than expected in the third quarter. Xiaflex experienced strong demand particularly in Peyronie's disease and the drug is expected to grow in the low-double-digits in 2017. However, since the announcement of the CDC guidelines, Endo continues to witness pressure in terms of prescription volumes in the opioid space.
The company also expects to see a modest decline in pain products. In addition, the earlier-than-expected generic entrant of Voltaren Gel has affected the 2016 outlook. Moreover, the reimbursement restrictions for Lidoderm further limit the use of the drug. The company thus expects Lidoderm sales to decline modestly. Endo expects a mid-to-high teen decline at the segment in 2016.
The Generics base business continues to be under pressure with revenues declining approximately 20% sequentially in third-quarter 2016. The decline can be attributed to deepening consortium pricing pressures, additional competitive entrants, product discontinuations as well as discrete factors, including destocking and shifts in purchase timing due to market conditions.
The business is expected to decline in low 30s in 2016. Steeper-than-anticipated consortium pricing pressures, both in and out of formal bid-cycles, could weigh on the company’s Generics business in the future and are likely to impact the adjusted gross margin profile.
On the fourth-quarter call, investors are expected to focus on the company’s performance. Updates on its restructuring efforts across the Generics product and R&D portfolio, as well as its manufacturing facility network are also expected by the investors.
Earnings Whispers
Our proven model does not conclusively show that Endo is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at -1.84%. This is because the Most Accurate estimate stands at $1.60 while the Zacks Consensus Estimate stand is pegged at $1.63. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Endo currently carries a Zacks Rank #5 (Strong Sell). As it is, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Endo International PLC Price and EPS Surprise
Endo International PLC Price and EPS Surprise | Endo International PLC Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) is expected to release results on Mar 1. The company has an Earnings ESP of +20% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Earnings ESP for Exelixis, Inc. (EXEL - Free Report) is +200% and it carries a Zacks Rank #2. The company is slated to release results on Feb 27.
Tesaro, Inc. has an Earnings ESP of +2.55% and a Zacks Rank #3. The company is scheduled to release results on Feb 28.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>